<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6620">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02007603</url>
  </required_header>
  <id_info>
    <org_study_id>AMPISUL/AMOXICLAV-HD_V1.4</org_study_id>
    <nct_id>NCT02007603</nct_id>
  </id_info>
  <brief_title>Concentration of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients</brief_title>
  <official_title>Multiple-dose Pharmacokinetics of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid During Haemodialysis in Longterm Haemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted to investigate the pharmacokinetics of ampicillin / sulbactam
      and amoxicillin/clavulanic acid during intermittent haemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Influence of hemodialysis on the area under concentration curve of ampicillin/sulbactam and amoxicillin / clavulanic acid plasma concentration levels.</measure>
    <time_frame>day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic samples are drawn on multiple timepoints from each patient during his participation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Infection During Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Ampicillin / sulbactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to the ampicillin / sulbactam arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin / clavulanic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to the amoxicillin / clavulanic acid arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of Amoxicillin / clavulanic acid</intervention_name>
    <description>Patients receive amoxicillin / clavulanic acid due to clinical necessity</description>
    <arm_group_label>Amoxicillin / clavulanic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin / sulbactam</intervention_name>
    <description>Patients receive ampicillin / sulbactam due to clinical necessity</description>
    <arm_group_label>Ampicillin / sulbactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blooddraws for pharmacokinetic profiling</intervention_name>
    <description>Blood will be sampled at multiple timepoints during multiple hemodialysis sessions</description>
    <arm_group_label>Ampicillin / sulbactam</arm_group_label>
    <arm_group_label>Amoxicillin / clavulanic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Suspected or proven bacterial infection requiring parenteral antibiotic therapy.

          -  Renal replacement therapy (HD)

        Exclusion Criteria:

          -  Known hypersensitivity to ampicillin / sulbactam, amoxicillin / clavulanic acid or
             other beta-lactames, or severe hypersensitivity (anaphylactic reaction) to
             beta-lactam antibacterial agents.

          -  An expected survival of less than two days.

          -  Known pregnancy

          -  Co-administration of one of the following drugs: probenecid which cannot be
             discontinued for the duration of the study

          -  Ampicillin / sulbactam respectively amoxicillin / clavulanic acid as monotherapy for
             resistant species or fungal infections.

          -  Other reasons opposing the study participation on the discretion of the
             investigators.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Thalhammer, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florian Thalhammer, Prof. MD</last_name>
    <phone>0043140400</phone>
    <phone_ext>4440</phone_ext>
    <email>florian.thalhammer@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Thalhammer, Prof. MD</last_name>
      <phone>0043140400</phone>
      <phone_ext>4440</phone_ext>
      <email>florian.thalhammer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Florian Thalhammer, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>October 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Florian Thalhammer</investigator_full_name>
    <investigator_title>a.o.Univ.-Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>chronic hemodialysis</keyword>
  <keyword>ampicillin</keyword>
  <keyword>sulbactam</keyword>
  <keyword>amoxicillin</keyword>
  <keyword>clavulanic acid</keyword>
  <keyword>pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Sulbactam</mesh_term>
    <mesh_term>Sultamicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
